grant

The effect of epigenetic DNA methylation on the progression of HPV-associated precancerous cervical lesions

Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 1 Feb 2021Deadline 30 Jun 2026
NIHUS FederalResearch GrantFY2026Active Follow-upAddressBehavioralBiological FunctionBiological MarkersBiological ProcessCancer ControlCancer Control ScienceCancer GenesCancer InductionCancer-Promoting GeneCancersCell BodyCell CycleCell Division CycleCellsCervicalCervical CancerCervical InjuryCervical Intraepithelial NeoplasiaCervical Intraepithelial NeoplasmsCervical spinal cord injuryCervix CancerCervix Intraepithelial NeoplasiaCervix Uteri Intraepithelial NeoplasiaCessation of lifeClinicalClinical DataClinical ManagementClinical ResearchClinical StudyCluster AnalysesCluster AnalysisCohort StudiesComplexCytosineDNA AlterationDNA MethylationDNA Sequence AlterationDataData SetDeathDetectionDevelopmentDisease OutcomeDisease ProgressionDoctor of PhilosophyEarly treatmentEnrollmentEpidemiologic MethodologyEpidemiologic MethodsEpidemiologic analysisEpidemiologic research methodologyEpidemiologic research methodsEpidemiological MethodsEpidemiological TechniquesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExhibitsFellowshipFemale HealthFutureGene ExpressionGenesGenetic AlterationGenomeGoalsGuanineGuidelinesGynecologic OncologyHPVHPV VaccinationHPV infectionHPV-High RiskHealth PrioritiesHigh Risk Oncogenic HPVHigh risk HPVHigh risk Human PapillomavirusHigh risk Human papilloma virusHuman Papilloma VirusHuman Papilloma Virus VaccinationHuman PapillomavirusHuman Papillomavirus VaccinationHuman papilloma virus infectionHuman papillomavirus infectionHypermethylationInfectious Human Wart VirusLearningLesionLondonMalignant Cervical NeoplasmMalignant Cervical TumorMalignant Neoplasm of the CervixMalignant NeoplasmsMalignant TumorMalignant Tumor of the CervixMalignant Tumor of the Cervix UteriMalignant Uterine Cervix NeoplasmMalignant Uterine Cervix TumorMalignant neoplasm of cervix uteriMapsMentorsMethodsMethods EpidemiologyMethods in epidemiologyMethylationMorbidityNetwork AnalysisNorth CarolinaOncogenesOutcomePathway AnalysisPh.D.PhDPhysiciansPremature BirthPrematurely deliveringPreterm BirthProliferatingResearchResearch SpecimenRiskRisk FactorsSamplingScientistSequence AlterationSiteSpecimenTCGATestingThe Cancer Genome AtlasTimeTrainingTransforming GenesUniversitiesUterine Cervix CancerUterine Cervix Intraepithelial NeoplasiaViral Gene ProductsViral Gene ProteinsViral ProteinsWomanWomen's HealthWomen's cohortactive followupbio-markersbiologic markerbiomarkerbiomarker identificationcancer carecancer epidemiologycarcinogenesiscarcinogenicitycareercervical carcinogenesisclinical significanceclinically significantcohort in womencohort on womencohort research studycohort surveycross-sectional investigationcross-sectional researchdevelopmentalearly therapyenrollepidemiologic evaluationepigeneticallyexperiencefemale cohortfollow upfollow-upfollowed upfollowupgenetic epidemiologic studygenetic epidemiologygenomic alterationglobal healthhigh riskhrHPVidentification of biomarkersidentification of new biomarkersimprovedinvestigate cross-sectionalmalignancymarker identificationmethylation biomarkermethylation markermethylation patternmortalityneoplasm/cancernovelpotential biological markerpotential biomarkerprecancerprecancerouspremalignantpremature childbirthpremature deliverypreterm deliveryprogression riskprospectivepublic health prioritiesscreeningscreeningsskillsstatisticsstudy cross-sectionalsurvey cross-sectionalvirus proteinwart virus
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
Reducing morbidity and mortality due to invasive cervical cancer (ICC) is a global health priority, which can be

accomplished in part by improving the timely detection and management of cervical precancer. Precancerous

cervical lesions characteristically progress from low-grade to high-grade cervical intraepithelial neoplasia (from

CIN-1 to CIN-2/3). Low-grade CIN-1 can spontaneously regress to normal, persist over time, or progress to CIN-

2/3, but there is insufficient evidence to predict which CIN-1 cases will progress. Epigenetic alterations of DNA

sequences, such as methylation at cytosine-p-guanine (CpG) sites, have been observed in cervical precancer

and cancer. As such, methylation patterns have been proposed as potential biomarkers for the detection of high-

grade cervical lesions. However, their utility as predictors of cervical disease progression is limited, as few

studies have investigated the effect of methylation on the risk of progression from low-grade CIN-1 to high-grade

CIN-2/3. In addition, while high-risk human papillomavirus (HPV) is known to cause ICC, little is known about

the relationship between HPV infection and the host methylation patterns seen in cervical carcinogenesis.

Epigenetic studies incorporating longitudinal clinical data are needed to understand the effect of DNA

methylation on the risk of progression of HPV-associated precancerous cervical lesions.

This study will assess relationships between early-stage DNA methylation, high-risk HPV infection, and the

progression or persistence of CIN-1. The proposed research will utilize collected data from women in the Cervical

Intraepithelial Neoplasia Cohort Study (CINCS) with CIN-1 at enrollment, baseline methylation at 450,000 GpGs,

pertinent clinical and behavioral exposures, and one year of clinical follow-up data. Using this unique and robust

dataset, the Specific Aims of this proposal are to 1.) assess the effect of baseline DNA methylation on CIN-

1 progression/persistence in 151 women at one-year follow-up and 2.) assess the association between

baseline HPV infection status and DNA methylation in 151 women with CIN-1.

Study findings have the potential identify novel methylation markers of cervical disease progression, improve the

clinical management of low-grade cervical precancer, and contribute to our knowledge of HPV-related

carcinogenesis. Through the completion of these research aims, the applicant will gain a unique set of skills in

advanced epidemiologic methods and clinical research, including the analysis and interpretation of complex

epigenetic and longitudinal clinical data. Expert mentors in cancer and genetic epidemiology, methylation

analysis, statistics, and gynecologic oncology will support the applicant’s successful completion of the proposed

research, associated training plan, and MD-PhD degree at the University of North Carolina at Chapel Hill. This

F30 fellowship will critically aid the applicant’s development as a future interdisciplinary physician-scientist

practicing at the intersection of cancer care, epigenetics, and women’s health.

Grant Number: 5F30CA257181-05
NIH Institute/Center: NIH

Principal Investigator: Alexandra Bukowski

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →